摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6S,7S)-6-{[4-(3-cyclopropylphenyl)-3,6-dihydropyridin-1(2H)-yl]carbonyl}-N-hydroxy-5-azaspiro[2.5]octane-7-carboxamide | 791829-79-3

分子结构分类

中文名称
——
中文别名
——
英文名称
(6S,7S)-6-{[4-(3-cyclopropylphenyl)-3,6-dihydropyridin-1(2H)-yl]carbonyl}-N-hydroxy-5-azaspiro[2.5]octane-7-carboxamide
英文别名
(6S,7S)-6-[4-(3-cyclopropylphenyl)-3,6-dihydro-2H-pyridine-1-carbonyl]-N-hydroxy-5-azaspiro[2.5]octane-7-carboxamide
(6S,7S)-6-{[4-(3-cyclopropylphenyl)-3,6-dihydropyridin-1(2H)-yl]carbonyl}-N-hydroxy-5-azaspiro[2.5]octane-7-carboxamide化学式
CAS
791829-79-3
化学式
C23H29N3O3
mdl
——
分子量
395.502
InChiKey
UCFPOZCPIVOGIJ-PMACEKPBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    81.7
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    羟胺 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 (6S,7S)-6-{[4-(3-cyclopropylphenyl)-3,6-dihydropyridin-1(2H)-yl]carbonyl}-N-hydroxy-5-azaspiro[2.5]octane-7-carboxamide
    参考文献:
    名称:
    Design and identification of selective HER-2 sheddase inhibitors via P1′ manipulation and unconventional P2′ perturbations to induce a molecular metamorphosis
    摘要:
    In an effort to obtain a MMP selective and potent inhibitor of HER-2 sheddase (ADAM-10), the P1' group of a novel class of (6S,7S)-7-[(hydroxyamino)carbonyl]-6-carboxamide-5-azaspiro[2.5]octane-5-carboxylates was attenuated and the structure-activity relationships (SAR) will be discussed. In addition, it was discovered that unconventional perturbation of the P2' moiety could confer MMP selectivity, which was hypothesized to be a manifestation of the P2' group effecting global conformational changes. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.10.108
点击查看最新优质反应信息

文献信息

  • Aza spiro alkane derivatives as inhibitors of metalloproteases
    申请人:——
    公开号:US20040259896A1
    公开(公告)日:2004-12-23
    The present invention provides a compound of Formula I or Formula II: 1 enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    本发明提供了公式I或公式II的化合物:1对映异构体,对映体,前药,溶剂化物,代谢物或其药学上可接受的盐,其中组分变量在此处提供。公式I和II的化合物是蛋白酶调节剂,可用于治疗与蛋白酶活性相关的疾病,如关节炎,癌症,心血管疾病,皮肤疾病,炎症和过敏症。
  • AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
    申请人:Yao Wenqing
    公开号:US20090124649A1
    公开(公告)日:2009-05-14
    The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    本发明提供了I式或II式的化合物:其对映异构体、顺反异构体、前药、溶剂化物、代谢物或其药学上可接受的盐,其中所述的组分变量已在此处提供。I和II式的化合物是蛋白酶的调节剂,并且在治疗与蛋白酶活性相关的疾病,例如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏症方面很有用。
  • AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
    申请人:Yao Wenqing
    公开号:US20110288068A1
    公开(公告)日:2011-11-24
    The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    本发明提供了化合物I或化合物II的化合物:对映体、顺反异构体、前药、溶剂化物、代谢物或其药学上可接受的盐,其中组成变量在此处提供。化合物I和II是蛋白酶调节剂,可用于治疗与蛋白酶活性相关的疾病,如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏症。
  • AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
    申请人:INCYTE CORPORATION
    公开号:US20140187530A1
    公开(公告)日:2014-07-03
    The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    本发明提供公式I或公式II的化合物:其对映体,顺反异构体,前药,溶剂化物,代谢物或其药学上可接受的盐,其中组成变量在此提供。公式I和II的化合物是蛋白酶调节剂,并且在治疗与蛋白酶活性相关的疾病,例如关节炎,癌症,心血管疾病,皮肤疾病,炎症和过敏症方面是有用的。
  • Aza spiro alkane derivatives as inhibitors of metallproteases
    申请人:Incyte Corporation
    公开号:EP2617419A1
    公开(公告)日:2013-07-24
    The present invention provides a compound of Formula (I) or Formula (II): enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula (I) and (II) are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    本发明提供了式(I)或式(II)化合物:其对映体、非对映体、原药、溶物、代谢物或药学上可接受的盐,其中组成变量在此提供。 式(I)和(II)化合物是蛋白酶的调节剂,可用于治疗与蛋白酶活性相关的疾病,如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏性疾病。
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯